Compare AbCellera Biologics Inc (ABCL) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Keysight Technologies Inc — how do they compare? AbCellera Biologics Inc trades at $7.21 (market cap $2.35B), while Keysight Technologies Inc trades at $315.41 (market cap $52.83B). The key difference: Keysight Technologies Inc is far larger — about 22.5× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | KEYS | |
|---|---|---|
Market Cap | $2.35B | $52.83B |
Sector | Health | Technology |
52-Week High | $8.12 | $373.34 |
52-Week Low | $2.78 | $158.51 |
Enterprise Value | $1.99B | $53.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Keysight Technologies (KEYS) trades at $309.12, down 1.51% today, with a bearish technical signal despite strong earnings beats in recent quarters. The company maintains solid profitability with a 63.67% gross margin and 17.31% net margin, though valuation multiples like a P/E of 51.49 appear elevated. Recent news highlights strategic collaborations in 6G and photonics, positioning KEYS for growth in AI and wireless markets.
The outlook is mixed: analyst consensus is bullish with a $390.30 price target (75% buy ratings), but technical weakness and high valuation pose near-term risks. Upside hinges on execution in high-frequency RF and photonics markets, while downside risks include competitive pressures and integration challenges from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
